Versatile Dyversity System at Leading European Cancer Research Centre Rapidly Analyses Fluorescent and Chemiluminescent Proteins with Ease
News May 06, 2010
Researchers at The Cancer Research UK Cambridge Research Institute (CRI) are using a Dyversity system to accurately analyse fluorescent and chemiluminescent Western blots labelled with various Qdot®s and ECL respectively. They are also using the system to image agarose gels containing DNA stained with SYBR® Safe DNA gel stain. The information from the gels and blots is being used to map genes and proteins associated with cancers and is helping scientists at the CRI to provide data, which could lead to the development of new therapies for these life threatening diseases.
The Dyversity system installed at the CRI contains a high-resolution 16 bit, CCD camera with intelligent control software specifically for chemiluminescence. Additionally, their system has a computer controlled lens that moves simultaneously with the motorised sample stage. This ensures the Dyversity can quickly focus to produce high quality images with perfect contrast, without any of the time consuming trial and error imaging usually associated with capturing images of chemiluminescent blots.
CRISPR Screening Reveals Sickle Cell Disease TargetNews
A key signaling protein, known as heme-regulated inhibitor (HRI), has been identified as a potential therapeutic target for the development of drugs to treat sickle cell disease, using a CRISPR screening approach.READ MORE
DNA Methylation Related to Liver Disease in Obese PatientsNews
DNA methylation implicated in initiation of liver fibrosis in non-alcoholic fatty liver diseaseREAD MORE
UCL Technology Fund Investment MeiraGTx Raises $75 Million in IPONews
MeiraGTx Holdings plc raised $75 million of gross proceeds upon close of the company’s initial public offering (IPO).READ MORE
International Conference on Neurooncology and Neurosurgery
Sep 17 - Sep 18, 2018